
Hologram Doctor: Not Who I'd Like to Visit, Says Ethicist
Hi. I'm Art Caplan. I'm at the Division of Medical Ethics, at NYU Langone Health System in New York City.
I am not a hologram. What am I talking about? Well, a new cancer clinic in Tennessee is starting to offer to its patients a hologram doctor.
Some of you will know what this is like. It's been used now in shows and performances, like at Sphere in Las Vegas. All of a sudden, you're able to go to a show by Michael Jackson, who is long since dead, but they can project him onto the stage. This is also true for other singers, performers, or even figures from the past. They're very realistic looking, and you feel like you're in the presence of maybe someone who's still alive.
That technology is being touted as a way to improve care for people in rural areas. Many of those folks have to travel very far to get regular exams and surveillance from a doctor or a nurse. Some of them require a 3- or 4-hour drive. It's a real burden. It's hard for many of these people, some of whom are frail, older, or sick from the treatments themselves. It's hard for them to get there.
The clinic has come up with this idea to make a hologram of a generic doctor, put that doctor in a studio with good lighting and good technology, and beam it out to the homes of these patients — or let them travel somewhere where the setup is a little more friendly that is maybe not 3 hours away. Maybe they could have studios that, for many people, are only an hour away.
I see some benefit. I think doing video conferencing and that style of thing often is a little cold and distant. The lighting isn't good, and the sound may be bad. It's not a professional production, and it may not give you the nuance and the detail that you want to see if you're trying to do an exam. It's better, if you will, to have the higher-level tech.
There are issues. One, in rural areas, we don't really have great Wi-Fi service. The rates of carrying detailed signals aren't that good. I'm not sure much of this is going to make it into a rural person's home. I still see travel required, which cuts back in some ways on the attractiveness. It may be better to send the actual doctor to four or five clinics once in a while than to try and rely on the hologram doctor going out to the rural patients at locations where the signal still is not going to be that great.
I also worry that for much of this work, while you can see some things, you can't see other things. Yes, you can detect a rash, and sure, you could see certain things about certain skin cancers, but are we really ready to say that we can conduct an exam remotely on a cancer patient with complicated disease? I'm not sure.
Again, I'm no oncologist, but it makes me nervous that a thorough exam would be something you could do. In a weird way, this might work better for dermatology. It might work better for certain kinds of family medicine practice, where someone's nervous about a rash, headache, or some symptoms that you could handle remotely. This patient group strikes me as maybe more complicated.
The other problem is the legal situation is unclear. What would it mean to make an error? What would it mean to actually give bad advice or misdiagnose? Who's responsible? Who's going to be able to hold someone accountable? What if the patient really isn't comfortable and doesn't give you all the information that they might if it was face-to-face?
In person, that whole area looks murky, unresolved, and even dangerous to practice in until the rules are laid out clearly about who's responsible for what and what the standard of care is for using this kind of technology.
Are we going to see more of it in the future? I think so. Is it ready for prime time now to an underserved rural population? I'm not sure it's here yet.
We'll have to keep an eye on it. Maybe improvements will come. Maybe our infrastructure for handling Wi-Fi and this kind of thing will improve, but for now, I'm not sure that the hologram doctor is the doctor that I'd want to visit.
I'm Art Caplan, at the Division of Medical Ethics at NYU Langone Health Systems. Thanks for watching.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合

Associated Press
an hour ago
- Associated Press
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals
NEW YORK CITY, NY / ACCESS Newswire / August 9, 2025 / New to The Street, one of the nation's longest-running business television brands, will broadcast Show #683 on Bloomberg today at 6:30 PM EST. This week's episode features four dynamic companies making waves in healthcare, biotech, blockchain gaming, and sports partnerships: BioVie Inc., FLOKI, PetVivo Holdings, Inc., and NRx Pharmaceuticals, Inc. The program, airing as sponsored programming, will also mark the television commercial debut of FLOKI, introducing the fastest-growing Valhalla Game to Bloomberg's national audience. Pedro Vidal, Chief Relationship Officer of FLOKI, discusses how the FLOKI Trading Bot has become the leader on the BNB Chain, giving traders advanced, user-friendly tools to maximize opportunities in the crypto market. Vidal also highlights the Valhalla Game's explosive success, where assets acquired in-game can be used in the real world - a groundbreaking integration of gaming and blockchain utility. Gamers are already winning Vera tokens, with over 100,000 Veras minted to date. For more information, visit and Jonathan Javitt, Founder, Chairman, and CEO of NRx Pharmaceuticals (NASDAQ:NRXP), discusses the Company's recent Citizen Petition to the U.S. Food and Drug Administration (FDA) seeking the removal of benzethonium chloride from all forms of ketamine sold in the United States. Benzethonium chloride, a preservative with known toxicity, is no longer allowed in hand cleansers, topical antiseptics, and many ophthalmic products. NRx has developed a preservative-free ketamine formulation with three-year stability, filed a supporting patent, and is pursuing FDA approval, including a potential labeled indication for treating suicidal depression under the FDA Commissioner's National Priority Voucher Program. Cuong Do, President and CEO of BioVie Inc. (NASDAQ:BIVI), provides an update on two ongoing Phase 3 clinical trials for Bezisterim. The first trial targets newly diagnosed Parkinson's patients entering therapy for the first time - potentially making Bezisterim the first new therapy for Parkinson's disease in more than 50 years. The second trial focuses on long COVID, specifically how Bezisterim may alleviate brain fog and fatigue, conditions affecting an estimated 17 million Americans. Both trials are expected to deliver top-line data in the first half of 2026. John Lai, CEO of PetVivo Holdings, Inc. (NASDAQ:PETV), joins Chase Chamberlin, Managing Partner at Commonwealth, to discuss their strategic partnership in the thoroughbred horse racing industry. Together, they aim to advance equine wellness by introducing PetVivo's innovative SPRYNG™ with OsteoCushion™ Technology into elite racing circles, offering a natural solution to maintain joint health in performance horses. About New to The Street For over 16 years, New to The Street has broadcast weekly as sponsored programming on Bloomberg Television and Fox Business, conducting more than 2,000 interviews with leaders from public and private companies. The brand operates the largest and fastest-growing digital business channel, New to The Street TV on YouTube, with over 3.16 million subscribers, delivering all-business, no-ads content. As a complete media ecosystem, New to The Street combines long-form television interviews, short-form TV commercials, iconic outdoor billboards, and the largest digital business platform to deliver predictable media for companies seeking to share their stories with investors, customers, and global audiences. For more information about upcoming episodes and featured companies, visit: Media Contact: Grace Bongiorno New to The Street [email protected] SOURCE: New to The Street press release
Yahoo
2 hours ago
- Yahoo
KCSO Deputy Gets Help with Cancer and Home Repairs
Kern County Sheriff's Deputy Jasmine Francisco is currently battling cancer while also facing unexpected financial hardship after discovering black mold in the home she had just purchased for her daughters. Solve the daily Crossword